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6.6), both p< 0.05. A greater proportion of schizophrenia caregivers reported at 
least one emergency room visit (26.1% vs. 20.2%) and hospitalization (20.4% vs. 
14.3%) than other caregivers, both p< 0.05. No significant difference was found 
on work-related impairment, probably due to the small sample of employed 
respondents. ConClusions: Schizophrenia caregivers reported greater activity 
impairment and more resource use than non-caregivers and caregivers of adults 
with other conditions. Better family and social support systems may help reduce 
the burden for schizophrenia caregivers.
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objeCtives: To investigate medication usage patterns, health care resource 
utilization and direct medical costs of patients with Major Depressive Disorder 
(MDD) in Beijing, China. Methods: Data were randomly extracted from Beijing 
Urban Employee Basic Medical Insurance Database. Patients who were aged ≥ 18 
years, with at least 1 primary diagnosis of MDD and 12-month continuous enroll-
ment after their first observed MDD diagnosis between 2012 and 2013 were identi-
fied. Those with a diagnosis of schizophrenia, bipolar disorder or cancer within the 
study period were excluded. Descriptive statistics were used to describe patient 
profiles, medication usage, health care resource utilization and costs. Results: 
A total of 8484 patients were included with mean (±SD) age of 57.15 (±15.34) 
years, 63.02% female and 94.47% having co-morbidities. 71.35% of patients were 
treated with antidepressant medications, including 60.53% of patients with SSRIs, 
followed by NaSSA (8.96%) and SNRIs (8.26%). Concomitant medications were 
prescribed for 76.78% of patients. Only 0.42% of patients experienced ≥ 1 MDD-
related hospitalizations during the 1-year follow up and the average annual num-
ber of hospitalization was 1.22 (±0.64) for those hospitalized patients. The length 
of stay was 33.38 (±30.6) days per hospitalization and 36.61 (±40.04) days per 
patient-year. All patients had ≥ 1 MDD-related outpatient visits. The mean annual 
number of outpatient visits was 3.06 (±2.99). The mean annual direct medical 
cost for all MDD patients was 1694.05 (±2513.71) RMB with 48.54% for antidepres-
sant medications, and that for hospitalized patients was 21290.97 (±16121.61) 
RMB with 15.03% for antidepressant medications and 66.45% for non-drug 
medical costs. ConClusions: In Beijing China, most MDD patients also had co-
morbid conditions and were mainly treated in the outpatient setting. SSRIs were 
the most commonly used antidepressants. The economic burden of MDD was 
considerable.
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objeCtives: Atomoxetine is the first medication to receive marketing authoriza-
tion in Spain for the treatment of newly diagnosed adults with Attention-Deficit/
Hyperactivity Disorder (ADHD). The aim of this analysis was to assess if treat-
ment with atomoxetine in adults with ADHD was cost-effective vs. placebo from 
the Spanish Healthcare System perspective. Methods: A Markov state tran-
sition model was developed for a theoretical cohort of newly diagnosed adult 
patients with moderate-severe ADHD. Key input data (response and discon-
tinuation) were derived from the atomoxetine trial program. Patients enter the 
model at the age of 18 and receive atomoxetine (initiated at 40mg for a week and 
then titrated to 80mg or 100mg) or placebo (in the absence of another authorized 
medication for the treatment of newly diagnosed adults with ADHD). Treatment 
success has been defined as response to treatment, showing improvements in 
both symptoms and functioning as measured by the CAARS and CGI-S scales, 
respectively. Treatment, non-specific health state utilities were populated with 
estimates from a vignette study in adults conducted in the UK. Drug and direct 
medical costs were obtained from local databases. In accordance with other 
published ADHD models, a 1-year time horizon was used. To check the model 
for robustness, probabilistic and deterministic sensitivity analyses were per-
formed. Results: Atomoxetine was found to be cost-effective with an ICER of 
€ 24,248/QALY despite patients in placebo arm only accumulating cost of physician 
visits. In addition, a QALY gain of 0.023 was projected, due to greater proportion 
of patients responding to treatment in the atomoxetine arm. Results from a 
probabilistic sensitivity analysis indicated that atomoxetine has a 57% probabil-
ity of being more cost-effective than placebo at a willingness to pay threshold 
of € 30,000/QALY in the Spanish setting. ConClusions: Atomoxetine is a cost-
effective option versus no active medical treatment for newly diagnosed adults 
with ADHD in Spain.
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objeCtives: Schizophrenia is a heterogeneous chronic disease with enormous 
economic consequences for the society. This study aimed at building a conceptual 
framework to evaluate the cost-effectiveness of Aripiprazole Once-Monthly (AOM) 
versus other atypical long-acting injectable (LAI) antipsychotics: Risperidone LAI 
(RLAI), Paliperidone Palmitate (PP) and Olanzapine Pamoate (OP) in the mainte-
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objeCtives: The objectives of this study are to estimate the prevalence of schizo-
phrenia in Switzerland and to assess its burden on patients, caregivers and society 
as a whole. Methods: A hospital registry was combined with a physician survey 
and health insurance claims data to capture all patients living in the northern part 
of the canton of Zurich. Total costs included direct medical and non-medical costs 
and lost production. All costs were calculated for the year 2012 from a societal 
perspective using a prevalence-based bottom-up approach. Intangible costs were 
expressed as quality adjusted life years (QALY) lost and were calculated from Swiss 
life tables, standardized mortality ratios and utility weights from the literature. 
Uncertainty and its sources were addressed in univariate and probabilistic sensi-
tivity analysis. Results: The point prevalence of schizophrenia in 2012 was esti-
mated at 0.39% of the Swiss population. The average annual costs of schizophrenia 
amounted to EUR 39,408 per patient and consisted of direct medical costs of EUR 
9,507 (24%), the costs of care by relatives and in residential homes of EUR 4,793 
(12%) and lost production of EUR 25,108 (64%). Inpatient hospital care accounted 
for EUR 6,242 per year or 66% of direct medical costs. The estimated reduction in 
life expectancy of 10.46 years and the utility decrement of 22.05 percentage points 
lead to intangible costs of 19.02 QALY per incident chronic case. ConClusions: 
The results of this study show the high burden of schizophrenia on patients, caregiv-
ers and society as a whole. The high costs of inpatient hospital care demonstrate 
the benefits of an effective prevention of relapse associated with hospitalization. 
Programs for the reintegration of schizophrenic patients into the labor market have 
a high potential to reduce the costs of schizophrenia considering the high burden 
of lost production and the early onset of the disease.
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objeCtives: Prescription opioid (“RxO”) abuse has not been regarded as a major 
problem in Europe so far, but a lack of reliable data hinders the assessment of this 
problem. This study aimed to derive estimates of the prevalence and excess costs 
of RxO abuse in the five largest European countries (France, Germany, Italy, Spain, 
and UK; “EU5”). Methods: Data from the European Monitoring Centre for Drugs 
and Drug Addiction and the UN Office on Drugs and Crime, on the prevalence of 
problem opioid abuse and the share of opioid abuse patients who report using 
non-heroin opioids, were used to estimate the prevalence of RxO abuse in the EU5. 
The costs of RxO abuse were calculated by applying published estimates of the 
excess health care costs of RxO abuse to country-specific estimates on the costs 
of chronic pain. Sensitivity analyses varied assumptions surrounding the preva-
lence of opioid abuse patients in the general population and the estimates of the 
excess costs of RxO abuse in the EU5. Results: The prevalence of RxO abuse, in 
the general population, varied between the EU5 countries, ranging from 0.7 per 
10,000 to 13.7 per 10,000. In the base case scenario, the total annual health system 
costs of RxO abuse across all EU5 countries were estimated to be € 323 million; results 
of sensitivity analyses ranged from € 98 million to € 730 million. These cost estimates 
included health system costs only; indirect costs were not included. ConClusions: 
RxO abuse imposes a burden on EU5 health systems. Future research should exam-
ine trends in the prevalence and total economic burden of RxO abuse in Europe 
over time and assess the potential benefits of abuse-deterrent formulations, which 
published research suggests have been associated with a significant relative reduc-
tion in rates of diagnosed opioid abuse.
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objeCtives: This study aimed to understand the impact of providing care for 
adults with schizophrenia on productivity, daily activities and resource utilization 
in the 5EU. Methods: Data from the 2010-2011 and 2013 5EU (France, Germany 
Italy, Spain, UK) National Health and Wellness Survey, an online questionnaire 
of a nationwide sample of adults (18+ years) was analyzed. Schizophrenia 
caregivers (n= 398) were matched to non-caregivers (n= 158,989) and other car-
egivers (n= 14,341) on baseline characteristics (sociodemographics, BMI, comor-
bid status) via propensity scores (1: 2). Outcome measures included health care 
utilization (type/number of resources used within the past 6 months) and Work 
Productivity and Activity Impairment questionnaire-based scores. Chi-square 
tests and ANOVAs were used to determine significant differences between 
schizophrenia caregivers vs. non-caregivers and other caregivers (e. g., cancer, 
Alzheimer’s). Results: The average age of schizophrenia caregivers was 45.3 
(SD= 15.8 years), 59.6% were female, and 52.5% were currently employed. After 
matching, schizophrenia caregivers reported greater activity impairment (38.4% 
vs. 26.1%), more health care provider visits (8.0 vs. 5.7), emergency room visits 
(0.9 vs. 0.2) and hospitalizations (0.8 vs. 0.1) than non-caregivers, all p< 0.001. 
Amongst employed respondents, schizophrenia caregivers reported greater 
absenteeism (12.4% vs. 5.6%), presenteeism (29.9% vs. 17.5%), and overall work 
impairment (35.0% vs. 20.7%) than non-caregivers, all p< 0.001. Comparing schizo-
phrenia caregivers and other caregivers, schizophrenia caregivers reported more 
activity impairment (38.4% vs. 32.3%) and health care provider visits (8.0 vs. 
